3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Glioblastoma
69
Glioma
26
Brain Neoplasms
26
Gliosarcoma
23
Melanoma
17
Central Nervous System Neoplasms
14
Astrocytoma
12
Neuroblastoma
10
Rhabdomyosarcoma
8
Small Cell Lung Carcinoma
6
Sarcoma, Ewing
6
Neoplasms
6
Neoplasm Metastasis
6
Medulloblastoma
6
Recurrence
5
Sarcoma
4
Ovarian Neoplasms
4
Osteosarcoma
4
Oligodendroglioma
4
Wilms Tumor
3
Prostatic Neoplasms
3
Neuroectodermal Tumors, Primitive, Peripheral
3
Ependymoma
3
Diffuse Intrinsic Pontine Glioma
3
Breast Neoplasms
3
Rhabdoid Tumor
2
Pancreatic Neoplasms
2
Optic Nerve Glioma
2
Lymphoma, Follicular
2
Lymphoma
2
Interventions
Carboplatin
23
Paclitaxel
14
pembrolizumab
8
liposomal doxorubicin
7
Bevacizumab
5
Specimen Handling
4
olaparib
3
niraparib
3
epacadostat
3
Topotecan
3
Taxes
3
Nivolumab
3
Magnetic Resonance Spectroscopy
3
Gemcitabine
3
Cyclophosphamide
3
Biopsy
3
sarilumab
2
rucaparib
2
poly ICLC
2
durvalumab
2
cemiplimab
2
STA 9090
2
Injections
2
Immunoglobulin G
2
Drug Therapy
2
Docetaxel
2
Disulfides
2
Cisplatin
2
veliparib
1
tremelimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Fallopian Tube Neoplasms
×
Temozolomide
×
Clear all
NCT05417594
2026-05-05
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled